The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
生物科技股在截至4月14日的一周内回落，与大盘同步。在假期缩短的一周内，以及即将到来的第一季度报道季节之前，新闻流动清淡。
Lyra Therapeutics, Inc. (NASDAQ:LYRA) was among the biggest gainers of the week following the completion of a $100.5 million private placement. Sierra Oncology, Inc. (NASDAQ:SRRA) also advanced strongly after it announced a deal to be acquired by GlaxoSmithKline plc (NYSE:GSK) for $1.9 billion.
莱拉治疗公司纳斯达克(Sequoia Capital：LYRA)是本周涨幅最大的股票之一，此前该公司完成了1.05亿美元的私募。塞拉肿瘤公司纳斯达克(Sequoia Capital：SRRA)也强劲上涨，此前该公司宣布将被葛兰素史克(纽约证券交易所代码：GSK)19亿美元。
Meanwhile, Kaleido Biosciences, Inc. (NASDAQ:KLDO) plunged after disclosing in a filing that it is shuttering operations. The microbiome therapeutic-focused biopharma was facing a cash crunch and clinical setbacks.
同时，卡莱多生物科学公司纳斯达克(Sequoia Capital：KLDO)在一份文件中披露将关闭业务后，股价暴跌。这家专注于微生物治疗的生物制药公司正面临资金短缺和临床挫折。
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) communicated the Food and Drug Administration's decision to delay granting full approval of its antibody cocktail REGEN-COV as a prophylactic treatment for COVID-19.
Regeneron制药公司新浪纳斯达克(新浪纳斯达克：REGN)通报了美国食品和药物管理局关于推迟完全批准其抗体鸡尾酒REGEN-COV作为新冠肺炎预防性治疗的决定。
Here are the key catalysts that could impact trading in biotech stocks in the unfolding week:
以下是可能影响未来一周生物科技股交易的关键催化剂：
Conferences
会议
2022 American Society of Cataract and Refractive Surgery, or ASCRS, Annual Meeting: April 23-26, in Washington, D.C.
2022年美国白内障与屈光手术学会年会：4月23-26日，华盛顿特区。
2022 Tandem Meetings – Transplantation & Cellular Therapy Meetings Of American Society for Transplantation and Cellular Therapy, or ASTCT, and Center for International Blood and Marrow Transplant Research, or CIBMTR: April 23-26, in Salt Lake City, Utah
2022年连续会议-美国移植和细胞治疗学会(ASTCT)和国际血液和骨髓移植研究中心(CIBMTR)的移植和细胞治疗会议：4月23-26日，在犹他州盐湖城
Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
相关链接：生物技术投资者请注意：在日历上标记4月份的PDUFA日期
Adcom Calendar
Adcom日历
FDA's Oncologic Drugs Advisory Committee is scheduled to meet on Friday, April 22 to discuss TG Therapeutics, Inc.'s (NASDAQ:TGTX) sNDA for Ukoniq (umbralisib) tablets, and BLA for ublituximab injection. The proposed indication for these two products is in combination for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA的肿瘤药物咨询委员会定于4月22日星期五举行会议，讨论TG治疗公司的(纳斯达克代码：TGTX)优康奈克片剂用sNDA，注射用乌比妥昔单抗用血乳酸。这两种产品的建议适应症是联合治疗患有慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤的成人患者。
The committee will also discuss the existing umbralisib indications in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma approved under accelerated approval regulations.
委员会还将讨论根据加速批准条例批准的复发或难治性滤泡性淋巴瘤和边缘带淋巴瘤患者的现有umbralisib适应症。
Clinical Readouts/Presentations
临床读数/演示
ASCRS Meeting Presentation(s)
ASCRS会议演示文稿
Ocular Therapeutix, Inc. (NASDAQ:OCUL): Phase 2 data for OTX-DED, an intracanalicular dexamethasone Insert, for the treatment of episodic dry eye disease (Saturday, 3:30-3:35 pm ET)
眼科治疗公司(纳斯达克：OCUL)：用于治疗发作性干眼病的OTX-DED的第二阶段数据(美国东部时间星期六下午3：30-3：35)
Earnings
收益
Johnson & Johnson (NYSE:JNJ) (Tuesday, before the market open)
Abbott Laboratories (NYSE:ABT) (Wednesday, before the market open)
Plus Therapeutics, Inc. (NASDAQ:PSTV) (Thursday, after the close)
Intuitive Surgical, Inc. (NASDAQ:ISRG) (Thursday, after the close)
强生(纽约证券交易所代码：JNJ)(周二，市场开盘前)
雅培(纽约证券交易所股票代码：ABT)(周三，市场开盘前)
Plus Treateutics公司(纳斯达克：PSTV)(周四收盘后)
直觉外科公司股份有限公司(纳斯达克：ISRG)(周四收盘后)
IPOs
首次公开募股(IPO)
IPO Quiet Period Expiry
IPO静默期到期
AN2 Therapeutics, Inc. (NASDAQ:ANTX)
AN2治疗公司(纳斯达克：蚂蚁)
Related Link: Merck Continues to See Executive Exodus; Here's A Look At All Recent Departures
相关链接：默克公司继续出现高管离职；以下是最近所有离职人员的情况